Lamisil

Terbinafine, the active ingredient in Lamisil, is a Allylamine antifungal presented as a tablet for oral use. It treats fungal infections of the skin, hair and nails, particularly in adults and adolescents who require systemic therapy. GNH USA supplies Lamisil as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lamisil is an oral allylamine antifungal indicated for infections caused by dermatophytes and related fungi. - Onychomycosis: eradicates the fungal pathogen within the nail plate, promoting normal nail growth. - Tinea pedis (athlete's foot): relieves itching and clears the infection on the feet. - Tinea corporis (ringworm): eliminates the fungal lesion on the body’s skin. - Tinea cruris (jock itch): resolves the infection in the groin area and reduces discomfort.

Common Side Effects: - Gastrointestinal upset: nausea, abdominal pain or dyspepsia. - Headache: mild to moderate intensity. - Skin reactions: rash, pruritus or mild erythema. - Altered taste: dysgeusia or loss of taste sensation. - Elevated liver enzymes: mild, transient increases.

Serious or Rare Side Effects: - Hepatotoxicity: hepatitis, jaundice or liver failure. - Severe cutaneous reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Hematologic abnormalities: neutropenia, agranulocytosis or eosinophilia. - Peripheral neuropathy: numbness or tingling in extremities. - Anaphylaxis: rare, potentially life‑threatening allergic response.

Before initiating therapy, consider the following precautions: - Assess liver function: obtain baseline hepatic enzymes and monitor periodically. - Monitor for skin reactions: discontinue if severe rash or blistering develops. - Avoid use in known hypersensitivity: do not prescribe to patients with documented allergy to terbinafine or other allylamines. - Review concomitant medications: evaluate for potential drug‑drug interactions. - Use with caution in renal impairment: adjust dosing if required. - Store at ambient temperature: keep in the original packaging, protect from moisture and heat.

Terbinafine may interact with several medicines, requiring careful management. Major Interactions (Avoid): - Itraconazole: combined use can increase risk of hepatotoxicity. - Cimetidine: may raise terbinafine plasma levels. - CYP2D6 inhibitors (e.g., quinidine): can elevate terbinafine concentrations. Moderate Interactions (Monitor Closely): - Alcohol: may exacerbate liver enzyme elevations. - Warfarin: monitor INR for potential anticoagulant effect changes. - Rifampin: may reduce terbinafine efficacy by inducing metabolism.